PRESS RELEASE
News
-
-
-
PRESS RELEASE
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics receives Notice of Allowance for European Patent covering RLF-TD011 for Epidermolysis Bullosa wound treatment. The patent will protect RLF-TD011 until 2040 in key European countries, with applications under review in other major markets -
-
PRESS RELEASE
HBM Healthcare Investments publishes Half-Year Report as at 30 September 2024 with key figures for the first six months of the 2024/2025 financial year
HBM Healthcare Investments AG releases Half-Year Report, showing a profit of CHF 23 million with positive NAV and share price growth. Private and public companies both contribute to earnings -
PRESS RELEASE
HBM Healthcare Investments publishes Half-Year Report as at 30 September 2024 with key figures for the first six months of the 2024/2025 financial year
HBM Healthcare Investments reports CHF 23 million profit and 1.5% NAV increase for the first six months ending September 2024, despite 5% negative currency impact -
PRESS RELEASE
We are delighted to invite you to our 3Q Trading Update Presentation Webcast: Thursday, October 31 2024 at 14:30 CET
Avolta AG invites you to the 3Q Trading Update Webcast on Oct 31 2024, 14:30 CET. CEO Xavier Rossinyol and CFO Yves Gerster will present in English. Q&A session included -
-
-
PRESS RELEASE
Pentixapharm’s CXCR4 Core Compound Subject of 17 Abstract Presentations at the Hamburg European Association of Nuclear Medicine (EANM)
Pentixapharm presents CXCR4 targeting compounds in 17 abstracts at EANM Congress, showcasing theranostic developments and research initiatives in various medical areas
